Fresenius Medical Care AG & Co. FMS reported fourth-quarter 2025 adjusted earnings per share (EPS) of 83 cents, which surpassed the Zacks Consensus Estimate by 23.9%. The bottom line surged 59% year ...
Ariel Investments, an investment management company, released its “Ariel Global Fund” fourth-quarter 2025 investor letter. A ...
Zacks Investment Research on MSN
Fresenius (FMS) is a top-ranked value stock: Should you buy?
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...
Fresenius Medical Care AG engages in the provision of products and services for individuals with renal diseases. It operates through the Care Enablement and Care Delivery segments. The Care Enablement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results